Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer.

Male Humans United States Prostatic Neoplasms, Castration-Resistant / radiotherapy Positron-Emission Tomography Treatment Outcome Precision Medicine Prostate-Specific Antigen
Lutetium-177 Multidisciplinary team Prostate cancer Radioligand therapy

Journal

Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 21 11 2022
revised: 08 02 2023
accepted: 10 02 2023
medline: 4 4 2023
pubmed: 19 3 2023
entrez: 18 3 2023
Statut: ppublish

Résumé

Prostate cancer (PC) is the second most commonly diagnosed cancer in the United States. Advanced PC evolves to metastatic castration-resistant PC (mCRPC). Theranostics combining prostate-specific membrane antigen-targeted positron emission tomography imaging and radioligand therapy (RLT) represents a precision medicine approach to PC treatment. With the recent approval of lutetium Lu 177 (

Identifiants

DOI: 10.1016/j.ctrv.2023.102524 PMID: 36933329
pubmed: 36933329
pii: S0305-7372(23)00015-4
doi: 10.1016/j.ctrv.2023.102524
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102524

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Dr. Calais reports grants from Lantheus, Novartis, and POINT biopharma,honoraria payments from Advanced Accelerator Applications, Astellas, Bayer, Curium Pharma, DS Pharma, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals, Lightpointmedical, Lantheus, Novartis, POINT biopharama, Progenics, Radiomedix, Sanofi, Telix Pharmaceuticals. Dr. Eulau reports no interests. Ms. Gardner reports no interests. Dr. Hauke reports payment for expert testimony from TeleDoc and leadership or fiduciary roles with Nebraska Oncology Society, Midwest Private Practice Associates ACO and ASCO. Dr. Kendi reports investigator fees from the VISION and PSMAfore studies at Mayo Clinic Rochester, Novartis Studies. Dr. Shore reports consulting fees from AbbVie, Amgen, Astrellas, AstraZeneca, Bayer, BMS, Boston Scientific, Clarity, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, Genesis Care, Invitae, Janssen, Lantheus, Lilly, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Photocure, Propella, PreView, Sanofi Genzyme, Sema4, Speciality Networks, Sesen Bio, Telix, Tempus, Tolmar, Urogen, Vaxijon, and payment for expert testimony from Ferring. Dr. Zhao reports consulting fees from AstraZeneca, EMD Serono, Exelixis, Janssen, Pfizer, Sanofi, and Seagen.

Auteurs

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, 650 Charles E. Young Drive South, Los Angeles, CA 90095, USA. Electronic address: jcalais@mednet.ucla.edu.

Stephen M Eulau (SM)

Swedish Cancer Institute at Swedish Medical Center, 1221 Madison Street, Seattle, WA, USA. Electronic address: Stephen.Eulau@swedish.org.

Linda Gardner (L)

Department of Nuclear Medicine, University of California, Los Angeles, 650 Charles E. Young Drive South, Los Angeles, CA 90095, USA. Electronic address: lgardner@mednet.ucla.edu.

Ralph J Hauke (RJ)

Nebraska Cancer Specialists, 17201 Wright Street, Suite 200, Omaha, NE 68130, USA. Electronic address: rhauke@nebraskacancer.com.

Ayse T Kendi (AT)

Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address: Kendi.Ayse@mayo.edu.

Neal D Shore (ND)

Carolina Urologic Research Center/GenesisCare, US, Myrtle Beach, SC 29572, USA. Electronic address: nshore@auclinics.com.

Song Zhao (S)

Swedish Cancer Institute at Swedish Medical Center, 1221 Madison Street, Seattle, WA, USA. Electronic address: Song.Zhao@swedish.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Incorporating radioligand therapy in clinical...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › États-Unis › Incorporating radioligand therapy in clinical...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Incorporating radioligand therapy in clinical...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Incorporating radioligand therapy in clinical...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Incorporating radioligand therapy in clinical...
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine de précision › Incorporating radioligand therapy in clinical...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigène spécifique de la prostate › Incorporating radioligand therapy in clinical...